The metabolic diseases company, Poxel SA, expects its novel antidiabetic, imeglimin, will be approved in Japan this year, through partner Sumitomo Dainippon Pharma Co., Ltd., and also believes the candidate is a Phase III-ready opportunity for a potential partner to develop for the US and EU.
The product is available as the previous EU/US licensee Metavant Sciences Inc said in November 2020 it would not move the candidate forward citing strategic reasons not related to efficacy or side effects; the Roivant